Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

Lunit is collaborating with Microsoft to help bring its AI-powered diagnostics for cancer detection into clinical practice.

Spirits companies have reason to be confident on Gen Z but where do they see growth and is developing a targeted approach the right answer?

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...

GlobalData, using its Ai Palette platform, presents the ingredients it believes offer opportunities for confectioners to win over snack lovers.

According to preliminary estimates, US Light Vehicle (LV) sales fell by 4.3% YoY in June, to 1.26 million units, reports GlobalData.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

Though GlobalData did not on Wednesday outline what it believes 2024 market expectations to be, broker Peel Hunt forecast revenue of GBP286 million for GlobalData, which would be a 4.7% increase ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Mexico could gain strategic benefits in the current trade environment, as companies look to relocate production within North ...

War risk cover, once a niche product, is re-emerging as a critical discussion point,' says data and analytics firm ...

The combined group could potentially 'almost double the joint second-largest players' market share', says analyst ...